Small-molecule estrogen-related receptor agonist · Fact sheet

SLU-PP-332

SLU-PP-332 activates estrogen-related receptors and has produced exercise-like metabolic effects in mice. It has not been established as an effective or safe substitute for exercise in humans.

Preclinical researchMostly animal or lab research

What is SLU-PP-332?

Estrogen-related receptors help regulate cellular energy metabolism; their name does not mean SLU-PP-332 is an estrogen supplement. It is a small molecule, not a peptide.

Benefits & claims

Endurance, fat loss, and improved mitochondrial function are the main interests. An exercise-like gene response is not the same as the full benefits of physical activity.

What the evidence supports

  • Mice showed improved exercise endurance in an initial study.
  • Other mouse experiments found metabolic and cardiac effects; each result depends on its experimental model.
Research areas
  • Exercise-related gene programs
  • Obesity models
  • Cardiac energy metabolism

Dosage & frequency

No established human regimen

SLU-PP-332 is a preclinical estrogen-related-receptor agonist. No established human exercise-mimetic dose or frequency is supported.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • It is a small molecule, not a peptide; mouse exposure cannot establish a human regimen.

Interactions & precautions

  • Human drug-interaction data are unestablished; preclinical exercise-mimetic activity does not establish medicine compatibility.

What is still unresolved

  • Human absorption, clinical efficacy, repeated-use safety, and interactions remain unestablished.

Side effects & risks

  • Human side-effect frequencies and interactions have not been established in the cited evidence.
  • Preclinical cardiac benefits do not establish cardiovascular safety in people.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

The cited experiments involve cell systems, mouse obesity models, and mouse pressure-overload heart failure. They do not establish human efficacy or safety.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Weight: reported experiences

Mixed account · personal report

Better workouts, sweating and persistent fatigue

A resistance-training adult initially reported more energy and focus with an oral product labeled SLU-PP-332. Later updates described better workout capacity alongside heavy sweating and fatigue that became difficult to tolerate. Weight loss occurred during a calorie deficit and added cardio.

Reported use in this account

Product
Product labeled oral SLU-PP-332 tablets
Amount
Initially 60 mg; later 20 mg, as reported
Frequency
Described daily use followed by three times weekly
Route
Oral tablets
Duration
About one month documented in the log

These observations all come from one person, not separate confirmations. Product identity is unverified, and diet, exercise and expectations prevent causal conclusions.

Read the account and follow-ups

Approval status

SLU-PP-332 has no FDA-approved therapeutic use. Its experimental findings should not be presented as a completed human clinical program.

Preclinical evidence; no FDA approval

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Human exposure and tolerability
  • Effects on real-world function and disease outcomes
  • Long-term effects of sustained receptor activation

Summary

SLU-PP-332 is a preclinical research compound. The phrase exercise mimetic describes a mechanism and mouse findings, not a proven human replacement for exercise.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedSLU-PP-332 and exercise capacity

    Cell and mouse experiments of estrogen-related receptor activation.

  2. pubmedSLU-PP-332 in metabolic syndrome models

    Mouse obesity and metabolic outcomes.

  3. pubmedPan-ERR agonists in experimental heart failure

    Cell and mouse studies; not a human heart-failure trial.

How we assess sources · Suggest a correction